Though Medicare is launching the GLP-1 Bridge program, offering enrollees temporary discounted access to GLP-1 medications ...

The Editors highlight three aspects of OMB’s recently proposed rule changes as particularly striking: that decisions on research funding would be made by political appointees, that funding could ...

Trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development.

In 832 patients with rare genetic disease, a conclusive diagnosis was made for 160 patients (19.2%) with long-read genome sequencing and for 137 patients (16.5%) with standard-of-care testing.

To the Editor: In the phase 3 GRADUATE trials of gantenerumab for early Alzheimer’s disease reported by Bateman et al. (Nov. 16 issue), 1 participants receiving gantenerumab had a greater decrease in ...

Hereditary angioedema is a rare and potentially life-threatening genetic condition characterized by recurrent and debilitating swelling attacks. Lonvoguran ziclumeran (lonvo-z) — an investigational, ...

When patients who have become homeless show a physician photos of themselves in better times, they are, in part, asking to be treated fairly, like they are people who might still turn their lives ...

A 47-year-old man with heart failure with a reduced ejection fraction and an ICD for the primary prevention of sudden cardiac death presented with an unheralded syncopal event, which had been captured ...

The Food and Drug Administration (FDA) mandated a safety study to be performed because of possible safety signals detected for the Janus kinase (JAK) inhibitor tofacitinib. As Ytterberg et al. report ...

Dr. Elias Zerhouni, director of the National Institutes of Health, discusses translational and clinical research and presents a new plan to provide additional financial support for this important a ...

Explore this issue of The New England Journal of Medicine (Vol. 393 No. 3).

On April 12, 1955, Jonas Salk's polio vaccine — made by inactivating poliovirus with formaldehyde — was declared to be safe and effective. The trial of Salk's vaccine had included 1.8 million children ...